• Illumina appointed Daniel M. Skovronsky to its board, effective June 16, 2026.
• Skovronsky is Eli Lilly’s chief scientific and product officer, leading global R&D and overseeing commercial products across major therapeutic areas.
• He founded Avid Radiopharmaceuticals in 2004, served as CEO, then joined Lilly in 2010 following its acquisition.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Illumina Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606230905PR_NEWS_USPR_____LA89644) on June 23, 2026, and is solely responsible for the information contained therein.